Xconomy

JULY 29, 2020

Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational study.

San Diego 87

San Diego Study Capital Invest 87

Xconomy

SEPTEMBER 6, 2019

In presenting clinical data from a Phase 3 study. If MedCo’s cholesterol-lowering drug inclisiran wins FDA approval, it will become the third entry in a new class of medicines that block a cholesterol-boosting protein called PCSK9. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 84

Pricing Class Study Marketing 84

Xconomy

AUGUST 11, 2016

government has ambitious plans for a long-term health study with one million Americans, and one of the world’s most powerful tech companies has a big part to play, including the storage of all the data on its “cloud” servers. It even has a price guide.). Those concerns are shared by the public.

PMI 40

PMI Study Google Research 40

Xconomy

JUNE 21, 2018

The San Francisco company priced its IPO late Tuesday, selling 6.25 Eidos will use the cash to fund studies of AG10 , a drug in mid-stage testing for transthyretin (TTR) amyloidosis, a progressive and fatal condition caused by the. million shares at $17 each, which was on the high end of its projected $15 to $17 range.

Study 72

Study Startup Pricing Funding 72

Xconomy

APRIL 6, 2018

The FDA didn’t smile upon a big submission of depression studies from Alkermes, while those fighting liver disease got a mixed slate of data as a big medical conference looms. There were plenty of policy and drug-price headlines, Read more » Reprints | Share: After the deals, we’ll move on to data.

Study 55

Study Pricing Conference Marketing 55

Xconomy

MAY 24, 2019

Patients, doctors, family members, and drug-price watchdogs continued to wait for the expected approval of Zolgensma , a Novartis (NYSE: NVS ) gene therapy for the rare inherited disease spinal muscular atrophy. Originally developed at a children’s hospital in Ohio , Zolgensma will be a litmus test for the nascent field.

Pricing 86

Pricing Marketing Develop Development 86

Xconomy

NOVEMBER 11, 2016

Drug company stocks got a boost with the defeat of Hillary Clinton, a vocal critic of drug prices. Will he take a softer stance on drug prices? But her near doubling of Trump (62 to 33 percent) didn’t translate into support for drug price controls. The Nitto drug is in a Phase 1b study. Now, the U.S.

Patents 87

Patents Study Pricing Research 87